CD19 and neoplasm: Tumor growth inhibition and overall tumor burden reduction were comparable between the melatonin-supplemented and control groups, indicating that melatonin does not interfere with the ability of CD19 CAR-T cells to effectively target and eliminate CD19-positive tumor cells.